Skip to main content
OB

ORIA Bioscience

ORIA Bioscience supplies ready-to-use, highly pure organelle preparations such as lysosomes and mitochondria, isolated with a patented microfluidic platform that preserves functional integrity. These scalable, cryopreserved products enable pharmaceutical and biotech R&D teams to run organelle-focused high‑throughput screens, improving hit‑to‑lead accuracy and reducing early‑stage development costs.

Paris, FranceFounded 2024193K+ followers
Updated 3 months ago

Funding

$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

2OGEN
Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Drug discovery programs often rely on whole-cell assays, which can obscure organelle-specific effects, increase assay variability, and raise early-stage R&D risk and cost.

Solution

ORIA Bioscience provides ready-to-use, highly pure organelle preparations—such as lysosomes (LYSO-Prep™) and mitochondria (MITO-Prep™)—isolated via a patented microfluidic platform. The gentle mechanical extraction preserves physiological integrity, delivering functional organelles at scale. Researchers can replace cell-based screens with organelle-focused assays, improving hit-to-lead accuracy and accelerating lead optimization. The preparations are compatible with standard high-throughput workflows, enabling faster go/no‑go decisions and reducing development expenses.

Target Audience

Primary customers are pharmaceutical and biotech R&D teams conducting early‑stage screening and lead optimization, particularly those focused on organelle‑targeted mechanisms across all therapeutic areas.

Features

  • Patented microfluidic isolation ensures gentle, controlled extraction and sorting of organelles, maintaining functional integrity
  • Highly pure, fully functional lysosome and mitochondria preparations delivered ready-to-use, eliminating in‑house isolation steps
  • Scalable production supports bulk orders for high‑throughput screening campaigns
  • Customizable organelle selections from specific cell types to match therapeutic area requirements
  • Compatibility with common assay platforms, including electrophysiology and biochemical readouts
  • Stable, cryopreserved formulations that retain activity across storage and shipping
This profile is AI-generated and may contain inaccuracies.